drugset / Trial / NCT02677181

Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT

NCT02677181

RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to determine the efficacy and safety of combined ATG (antithymocyte globulin ) regimen for aGVHD(acute graft-versus-host disease ) prophylaxis in matched sibling donor peripheral blood stem cell transplantation (MSD-PBSCT).

Timeline

Start
2016-01
Primary completion
2020-01
Completion
2022-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ATG Protein / enzyme biologic 3.5 mg/kg
Background CsA Unknown 3 mg/kg Intravenous
Background Methotrexate Small molecule 10 mg/m2
Background Mycophenolate Mofetil Small molecule 0.5 g Oral